Showing results (51-60 of 236) with videos related to
Sort By:
Pageof 24
Infectious Diseases and Therapy|February 20, 2020
Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative OrganismsJanet Y Wu, Pavithra Srinivas, Jason M PogueAntimicrobial Agents and Chemotherapy|May 7, 2014
Impact of different antimicrobial therapies on clinical and fiscal outcomes of patients with bacteremia due to vancomycin-resistant enterococciKayoko Hayakawa, Emily T Martin, Uma Mahesh Gudur, et al.Infection Control and Hospital Epidemiology|May 16, 2025
Usage of oral vancomycin for acute <i>Clostridioides difficile</i> infection (CDI) resulting in later acquisitions of vancomycin-resistant enterococci (VRE)Evgeny Rogozin, Husam Maree, Majdi Masarwi, et al.Antimicrobial Agents and Chemotherapy|May 2, 2012
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coliTeena Chopra, Dror Marchaim, Jennifer Veltman, et al.BMC Infectious Diseases|January 7, 2022
Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019Jason M Pogue, Yun Zhou, Hemanth Kanakamedala, et al.Expert Review of Anti-Infective Therapy|September 14, 2017
Intravenous fosfomycin for the treatment of hospitalized patients with serious infectionsAndrew F Shorr, Jason M Pogue, John F MohrClinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 19, 2018
Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary ConsiderationsJason M Pogue, Robert A Bonomo, Keith S KayeVirulence|July 8, 2016
Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant EnterobacteriaceaeJoshua T Thaden, Jason M Pogue, Keith S KayeInternational Journal of Antimicrobial Agents|November 24, 2016
Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?Jason M Pogue, Jessica K Ortwine, Keith S KayeInfectious Diseases and Therapy|July 12, 2020
That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19Matthew R Davis, Erin K McCreary, Jason M PoguePageof 24